Market News
Stay updated with the latest market trends, earnings, and economic indicators.
LIVE: Nifty fails to hold 24,000; metals outperform | Closing Bell
Markets ended lower, snapping a two-day winning streak, with benchmark indices pressured by weakness in financials and select heavyweight stocks. The Sensex declined over 300 points, while the Nifty failed to hold above the crucial 24,000 mark. Market breadth remained weak, with decliners outnumbering advancers by nearly two-to-one on the BSE, reflecting broad-based selling. Investor caution was also evident as the India VIX climbed around 5%, indicating a pickup in volatility expectations. On the sectoral front, pharma and metal stocks bucked the trend, with the Metal index snapping a three-session losing streak. Banking stocks remained under pressure, dragging the Bank Nifty below the 58,000 mark. Among the Nifty 50 gainers, Dr Reddy's, Max Healthcare and Trent led the advances, while Kotak Mahindra Bank, Mahindra & Mahindra and IndiGo were among the biggest losers of the session.
Buy Rubicon Research; target of Rs 955: Motilal Oswal
Motilal Oswal is bullish on Rubicon Research recommended buy rating on the stock with a target price of Rs 955 in its research report dated April 15, 2026.
Buy Laurus Labs; target of Rs 1280: Motilal Oswal
Motilal Oswal is bullish on Laurus Labs recommended buy rating on the stock with a target price of Rs 1280 in its research report dated March 19, 2026.
Buy Laurus Labs; target of Rs 1280: Motilal Oswal
Motilal Oswal is bullish on Laurus Labs recommended buy rating on the stock with a target price of Rs 1280 in its research report dated February 25, 2026.
Neutral ALKEM Laboratories; target of Rs 5525: Motilal Oswal
Motilal Oswal recommended Neutral rating on ALKEM Laboratories with a target price of Rs 5525 in its research report dated February 14, 2026.
Neutral Eris Lifesciences; target of Rs 1520: Motilal Oswal
Motilal Oswal recommended Neutral rating on Eris Lifesciences with a target price of Rs 1520 in its research report dated February 14, 2026.
Neutral Lupin; target of Rs 2360: Motilal Oswal
Motilal Oswal recommended Neutral rating on Lupin with a target price of Rs 2360 in its research report dated February 14, 2026.
Neutral Torrent Pharma; target of Rs 4300: Motilal Oswal
Motilal Oswal recommended Neutral rating on Torrent Pharma with a target price of Rs 4300 in its research report dated February 14, 2026.
Buy Five Star Business Finance; target of Rs 600: Motilal Oswal
Motilal Oswal recommended is bullish on Five Star Business Finance recommended buy rating on the stock with a target price of Rs 600 in its research report dated Jun 22, 2026.